Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

This study aims to evaluate s...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Despite recent developments in cancer diagnostics and treatment modalities, mortality rates maintain high in non-small cell lung cancer (NSCLC)[1]. One of the factors contributing to high mortality rates is progressive unintentional weight loss of body weight and muscle mass (i.e. cachexia [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Multimodality therapy is the current standard of care for resectable stage III non-small cell lung cancer (NSCLC). Approximately 10% of all NSCLC cases present as stage IIIA-N2, and for these individuals, disease control and overall survival (OS) remain poor, with 5-year survival rates of 23% [1]. Based on randomized trials and a meta-analysis demonstrating improved OS with the addition of induction chemotherapy (CT) plus surgery versus surgery alone, induction chemotherapy is a reasonable option for resectable stage IIIA-N2 NSCLC [2,3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionIn clinical practice, approximately 70% of patients with unresectable stage III NSCLC would be eligible to receive consolidation therapy with durvalumab.
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
nning Schmidt Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on histology, there are two major subtypes: Non-small cell lung cancer (NSCLC) (the more frequent subtype), and small cell lung cancer (SCLC) (the more aggressive one). Even though SCLC, in general, is a chemosensitive malignancy, relapses following induction therapy are frequent. The standard of care treatment of SCLC consists of platinum-based chemotherapy in combination with etoposide that is subsequently enhanced by PD-L1-inhibiting atezolizumab in the extensive-stage disease, as the addition of immune-checkpoint inhibit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Immune checkpoint inhibition has profoundly improved survival in a subset of patients with advanced nonsmall cell lung cancer (aNSCLC) [1 –4]. As many as 68% of NSCLC tumors express programmed death ligand 1 (PD-L1); binding of PD-L1 to programmed death protein 1 (PD-1) on activated T cells prevents an antitumor immune response [4]. Pembrolizumab, a humanized IgG4 monoclonal antibody to PD-1, inhibits its interaction with PD-L1 [1]. As a first line treatment for aNSLC patients with a PD-L1 tumor proportion score (TPS) ≥ 50% not harbouring genomic tumor alterations (i.e., Epidermal Growth Factor Receptor (EGFR) mut...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Authors: Jeong JH, Choi PJ, Yi JH, Jeong SS, Lee KN Abstract Spontaneous regression of lung cancer is a very rare and poorly understood phenomenon. A 64-year-old man presented to Dong-A University Hospital with a shrunken nodule in the right lower lobe. Although the nodule showed a high likelihood of malignancy on needle aspiration biopsy, the patient refused surgery. The nodule spontaneously regressed completely in the next 17 months. However, the subcarinal lymph node was found to be enlarged 16 months after complete regression was observed. We pathologically confirmed metastasis of squamous cell carcinoma and pe...
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
Authors: Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A Abstract BACKGROUND: Despite recent advances in targeted therapy and immunotherapy for advanced non-small cell lung cancer (NSCLC), carboplatin/pemetrexed/bevacizumab remains a commonly used first-line regimen. However, it is unknown whether the addition of bevacizumab to carboplatin/pemetrexed improves overall survival (OS). MATERIALS AND METHODS: Using nationally representative curated electronic health record data from Flatiron Health, we performed a retrospective cohort study of patients diagnosed with advanced nonsquamous NS...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Non-Small-Cell Lung Carcinoma Interventions:   Biological: Pembrolizumab 200 mg;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Dietary Supplement: Folic acid 350-1000 μg;   Dietary Supplement: Vitamin B12 1000 μg;   Drug: Dexamethasone 4 mg;   Drug: Saline solution Sponsor:   Merck Sharp & Dohme Corp. Active, not recruiting
Source: - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Study